The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to provide up to $384m in funding to support Novavax in the development and manufacturing of Covid-19 vaccine candidate, NVX-CoV2373.

This funding is in addition to the initial $4m offered by the CEPI in March.

Novavax will use the funds to conduct a Phase I/II clinical trial of the vaccine. The Phase I part is set to begin this month in Australia; the Phase II part will be conducted in various countries based on the Phase I top-line data expected in July.

The company started testing its candidates in animal models in February.

Novavax president and CEO Stanley Erck said: “CEPI plays a vital role in advancing innovative technologies against the Covid-19 pandemic. Their partnership and support allows Novavax to leverage its innovative vaccine platform and expertise in this global crisis.

“For the last few months, the entire Novavax team has been working nonstop in an ongoing effort to make our vaccine a reality, and we appreciate CEPI’s confidence in our technology platform and our progress.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest CEPI investment will also be used to scale-up the NVX-CoV2373 vaccine antigen and the company’s Matrix-M adjuvant, intended to boost immune responses by triggering high levels of neutralising antibodies.

Novavax will focus on process development for scaled-up production. The aim is to enable manufacturing of up to 100 million vaccine doses by the end of this year.

The CEPI funding could also help the company boost its large-scale manufacturing capacity in multiple locations, with a goal to produce more than one billion doses next year.

Commenting on the investment, CEPI CEO Richard Hatchett said: “Our vaccine R&D programmes are starting to show progress, so it is vital that we invest now to boost manufacturing capacity so that our partners have the ability to produce vaccines at a global scale.

“We still have a long way to go, but we’re making important steps forward to deliver a safe, effective, and globally accessible vaccine as quickly as possible.”